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terms of observable characteristics such as age, gender, and comorbidities
(p0.001). Samples were balanced with nearest neighbor matching. Then seg-
mented time-series models were applied. There was a significant association be-
tween the onset of intervention and the level of utilization of these drugs.
CONCLUSIONS: To isolate the effects of guidelines, we need to control for three
different factors: 1) baseline differences between the two groups; 2) stepwise dif-
ferences at the intervention point; and 3) trend differences after the intervention.
We showed that propensity scorematching can be used for the first factor, and the
latter two can be controlled with the interrupted time-series model.
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THE BURDEN OF CAREGIVING: ASSESSING THE STATUS OF CURRENT CLINICAL
RESEARCH
Hamer N, Costello S, Roper S, Hamerslag L
Costello Medical Consulting Ltd, Cambridge, UK
OBJECTIVES: The burden of caregiving is high. In 2009 therewere an estimated 65.7
million caregivers in the U.S. (29% of the adult population) and these numbers are
expected to swell in the coming years with the ageing population. Caregiving im-
pacts on the health, wellbeing and work productivity of the caregiver, therefore
research aimed at assessing and reducing the burden of caregiving is warranted.
The objective of this study was to assess the status of current clinical research into
the burden of caregiving. METHODS: Clinicaltrials.gov was searched for trials
where caregiver burden (CB) was reportedly measured. Information on the care-
recipient condition (CRC), the primary focus of the study, and the type of interven-
tion being considered, was extracted from the included trials. RESULTS: 80 trials
were identified that measured a reported outcome of CB. The most common CRC
was Alzheimer’s disease and related disorders (34 studies); followed by cancer (14),
frail and elderly (8), mental health (7), Parkinson’s disease (7), brain and spinal cord
injury (5) and ‘other’ (5). A range of questionnaire-based instruments were report-
edly used across studies to elucidate the physical, emotional (psychological), social
and financial impacts of caregiving.The role or burden of the caregiver was a key
focus in 55% of the studies; trials involving care of cancer patients had the highest
proportion of caregiver-focused studies (12/14, 86%). Behavioural and drug inter-
ventions were the most frequently investigated intervention type (38% and 25% of
trials, respectively), although no studies investigating a ‘drug’ intervention evalu-
ated the effect on caregivers as a primary outcome. CONCLUSIONS: Current clini-
cal research into the burden of informal caregiving is concentrated in age-related
CRCs. Research interventions aimed at relieving CB are mostly behavioural in na-
ture. The growing number of caregivers means that research into effective meth-
ods of reducing CB will be of ever increasing importance.
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WHAT IS IMPORTANT DURING THE PHARMACOECONOMIC EVALUATION OF
CAM (COMPLEMENTARY AND ALTERNATIVE MEDICINE)?—A SURVEY
RESEARCH
Zhang F1, Li SC2, Fu S1, Xie J1, Zhang Y1, Kong L1
1Shenyang Pharmaceutical University, ShenYang, Liaoning, China, 2University of Newcastle,
Callaghan, NSW, Australia
OBJECTIVES: The increasing popularity of Complementary and Alternative Medi-
cine (CAM) leading to an increasing interest of CAM assessment through phar-
macoeconomic evaluation. The attempts, however, have been unsatisfactory. This
study attempted to survey expert practitioners in China of TCM (Traditional Chi-
nese Medicine) which is a major part of CAM to elucidate critical issues when
assessing cost-effectiveness of TCM, and to ascertain influencing factors of mea-
suring HR-QOL in TCM. METHODS: A questionnaire (with 20 close and open-end
questions) was distributed to TCM practitioners who had been working in the field
for at least 5 years and had published at least one related paper in the last 5 years.
The questions were divided into two modules with module 1 about the issues of
pharmacoeconomic of TCM, andmodule two about the influencing factors of mea-
suring HR-QOL in TCM. Correlation and Partial Correlate test using age and profes-
sional field as control variable were used to module 1 and 2 respectively, non-
related factors were excluded. Principal Component Analysis (PCA) was performed
for remaining items. RESULTS: Of 429 questionnaires issued, 137 were recovered
from 31 medical and research institutions of 8 provinces and cities in China giving
a recovered rate 31.93%. Module 1 and 2 all passed the KMO and Bartlett’s test of
sphericity test (kmomodule 10.56, kmomodule 20.66). Module 1 extracted 4 common
factors after the Rotation Factor Analysis with cumulative variance of 69.9%, while
Moduel 2 extracted 3 with cumulative variance of 70.6%. CONCLUSIONS: The com-
mon factors fromModule 1 prompted us to pay attention to during the pharmaco-
economic evaluation: patient preference; long-term outcomes; the alternative of
TCM; and the overall economic burden of patients.The common factors fromMod-
ule 2 required us to note during the HR-QOL research: Acceptance level of the
measurement scale by patients and physicians; disease complexity; and whether
HR-QOL scale reflects the characteristics of TCM.
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A REVIEW AND CLASSIFICATION OF CONTINGENT VALUATION METHOD
STUDIES IN SUB-SAHARA AFRICA
Kangethe AW, Franic D
University of Georgia, Athens, GA, USA
OBJECTIVES: The primary objective is a review, classification and critical appraisal
of contingent valuationmethod (CVM) healthcare studies conducted in Sub-Sahara
Africa based on criteria by O’Brien and Gafni (1996). The secondary objective is to
determine the impact of the Bamako Initiative adopted in the early 1990s on CVM
studies in the same setting. METHODS: CVM African healthcare studies (willing-
ness to pay (WTP) and willingness to accept (WTA)), were identified using a com-
prehensive literature search in EconoLit, Google Scholar, Medline, PubMed and
Web of Science between 1981 to 2010. CVM studies evaluated included WTP and
WTA studies reporting primary data were included for evaluation. Primary assess-
ment of the studies was based on the conceptual framework for evaluation of
contingent valuation of healthcare programs (5 Items)(O’Brien and Gafni 1996).
Secondary assessment was based on the time horizon of publication: pre-, during-
(1990s), or post- BI, and area of intervention. RESULTS: Twenty-four CVM studies
were evaluated: all used WTP and compensating variation. Elicitation techniques
were dominated by bidding game (42%), followed by dichotomous choice (33%), and
then payment card and the open ended formats (12.5%). Majority of studies (83%)
were published after 2000, the remainder were published in the 1990s. Interven-
tions included insurance (25%), medication (38%), and health services (38%).
CONCLUSIONS: Healthcare CVM studies in Sub-Sahara Africa are limited despite
the introduction of Bamako Initiative. The predominance of the bidding game elic-
itation technique in evaluated studies may be a reflection of the actual African
market conditions. There is continuing debate as to which is the most appropriate
CVM for healthcare studies conducted in Africa This debate will continue until
these methods are compared to actual markets. CVM studies may start to engage
the political market as Africa moves towards universal health coverage.
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DEVELOPMENT OF AN INCREMENTAL COST-EFFECTIVENESS RATIO WITH
SOME EQUITY IMPLICATION
Wang JD1, Hung MC2
1National Cheng Kung University College of Medicine, Tainan, Taiwan, 2National Taiwan
University, Taipei, Taiwan
OBJECTIVES: The conventional ICER (incremental cost-effectiveness ratio), which
quantifies howmany dollars are spent per QALY (quality-adjusted life year) gained
from a specific health technology, has been criticized as unfair to the aged and/or
physically challenged. METHODS: By taking the position that every life is equally
important and every citizen is entitled to access health care services for the entire
duration of his/her life expectancy, we replace the denominator of the conven-
tional ICER, with the proportion of life, which is the quality-adjusted life expec-
tancy (QALE) gained from the specific health technology divided by the QALE of the
corresponding age- and gender-matched general population. The numerator is
converted to the additional monetary cost spent over a lifetime after adjustment
for annual discount rate. The new indicator quantifies howmany dollars are spent
to save the life of a person with a specific illness, and how much can be saved by
preventing the occurrence of that illness. RESULTS: We have applied the estima-
tion method to compare patients with liver cancer; breast cancer, acquired immu-
nodeficiency syndrome, maintenance hemodialysis and peritoneal dialysis, and
prolongedmechanical ventilation.CONCLUSIONS: Because the proposed indicator
accounts for a fair opportunity for the aged and disabled more than the conven-
tional ICER does, we recommend that this indicator be applied in future delibera-
tions of health care resource allocation.
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DRUG DEVELOPMENT AND PHARMACEUTICAL PRICING IN THE UNITED
STATES: THE INFLUENCE OF DRUG INTENDED OUTCOMES OF DRUG PRICING
Iaconi A, Khalidi N, Olanrewaju O, Balkrishnan R
University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: Determination of the price of a drug starts in its early developmental
stages and it is driven by various competitive healthmarket forces. The purpose of
the study is to explore associations between pharmaceutical pricing and the value
of drugs. METHODS: Based on FDA indications we have identified three different
drug categories: life saving drugs, drugs that are not life saving but save lives
overtime, and drugs that only treat disease symptoms and affect QOL. We have
investigated our theory of an association between drug intended outcomes and the
price tag placed on a drug by performing a literature review of cost analyses for
drugs selected in each category. The literature review included a combination of
key words such as the name of the drug, cost-effectiveness, cost-utility, and QALY.
We identified articles from the past 10 years published only in the English lan-
guage. For each drug, studies reporting ICER/QALY values were selected. ICER/
QALY data were recorded and the values of the three categories were compared
among each other and with the published acceptable QALY threshold value of
US$64,000.RESULTS: For the life saving drugs group the highest ICER/QALY value is
US$150,843 and lowest is €6,880, for the disease ameliorating drugs group €105,599
and US$544, and for the drugs treating disease symptoms and affecting QOL
£154,831 and $US1,056 respectively. Themajority of drugs in the first categorywere
found to have ICER/ QALY values greater than the $64,000 value, while themajority
of the drugs selected in the second and third categories were found to have ICER/
QALY values smaller than the $64,000 value. CONCLUSIONS: From our study we
have found that drugs that are life saving aremore likely to have ICER/QALY values
greater than the threshold values compared to drugs that are disease ameliorating
and that are designed to improve patients’ QOL.
PRM8
LEGAL RESTRICTIONS ON THE USE OF QALYS IN PHARMACOECONOMIC
ANALYSIS IN GERMANY
Gissel C, Goetz G, Repp H
Justus Liebig University Giessen, Giessen, Hessen, Germany
OBJECTIVES: In contrast to theNational Institute for Health and Clinical Excellence
(NICE), the German Institute for Quality and Efficiency in Health Care (IQWiG) does
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not use quality-adjusted life years (QALYs) in its efficiency frontier approach to
pharmacoeconomic evaluation. The lack of a global measure of effectiveness
across indications is subject to criticism by international experts. In response,
IQWiG refers to German legal restrictions. The objective of this analysis is to ex-
amine whether German legislation allows the use of QALYs in pharmacoeconomic
evaluation.METHODS:We employ a legal analysis of German legislation concern-
ing the provisions relevant to pharmacoeconomic analysis by IQWiG. Our analysis
includes specific pharmacoeconomic provisions, constitutional restrictions and
jurisdiction. RESULTS: According to German Social Code Book V, IQWiG’s phar-
macoeconomic evaluation is to be based on international standards. This could
hint at the NICE’s use of QALYs if the existence of an international standard is
assumed in the first place. The Federal Constitutional Court of Germany, however,
has consistently stressed life and health as most important fundamental rights in
the German constitution. German jurisdiction has interpreted the German consti-
tution as prohibiting putting amonetary value on life or health. However, the global
use of QALYswould imply putting an explicit or implicit threshold value on aQALY,
i.e. a value on life and health. Therefore, IQWiG’s reluctance to use QALYs in its
method is justified by legal restrictions as imposed by the German constitution.
CONCLUSIONS: Our analysis shows that English standards cannot be adopted
without considering legal restrictions in the German context. These restrictions
prohibit the use of QALYs. The use of QALYs is motivated by the assumption of a
fixed health care budget. The German legislator confirmed its rejection of this
assumption by increasing Statutory Health Insurance contributions from 14.9 % to
15.5 %, effective January 2011.
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OBJECTIVES: Analysis of pharmacoeconomic studies (FES), held in the Republic of
Kazakhstan between 2005 and 2010. METHODS: Produced an information search
using keywords pharmacoeconomics, clinical and economic analy-
sis. It was analyzed 81 scientific researches of national researchers which was
published in the republican (national) publications. RESULTS: Among the papers
was dominated pharmacoeconomic studies (FES) in the therapeutic (bronchial
asthma, COPD, hypertension, peptic ulcer, etc.) and psychiatric practice (mostly -
Pharmacoeconomics of neuroleptics). Studies of the clinical and economic aspects
for health technology assessments are not found. Selection of FES carried proac-
tive. Among the methods of pharacoeconomic analysis (FEA) the most frequently
used analysiswascost of disease. Cost-effectiveness analysiswas used in 23
(28%) studies. Incremental analysis was performed only in 2 FES. Analysis of the
costminimizationwas usedmethodologically correct only in 2 papers.Mod-
eling in the FES was used in 10 (12%) studies. Another 6 (0.7%) works extrapolated
the results of foreign researchers, taking into account the national clinical practice.
Others were presented reviews of popularization of pharmacoeconomics, ABC and
VEN-analysis of various medical organizations. CONCLUSIONS: In Republic of Ka-
zakhstan pharmacoecnomics is at an early stage of development. There is a need to
update and deploy the FES on the background of the proper use themethodology of
pharmacoeconomics, the definition of a coordinator and a real consumer FES, im-
provement of legislation provision for such research.
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IS IT FEASIBLE TO COLLECT QUALITY OF LIFE DATA ELECTRONICALLY IN THIN -
A UK GENERAL PRACTICE DATABASE?
Blak BT, Lee J, Thompson M, Bourke A, Pinder L
Cegedim Strategic Data Medical Research Ltd, London, UK
OBJECTIVES: Quality of life (QoL) information is increasingly used in research. This
pilot study evaluated the feasibility of collecting electronic QoL data in UK general
practices that can be linked to patients’ anonymous electronic medical records.
METHODS: Patients18 years who visited one of three practices contributing data to
The Health Improvement Network (THIN) database during a 31-day period were in-
cluded. Patients were asked to complete an experimental electronic questionnaire
based on the EQ5D questionnaire and EQ5Dvas (Visual Analogue Scale) on a personal
digital assistant (PDA) (PocketVision, Inchware).Datawereanalysedandeachpractice
was interviewedshortly after studyend for feedback.Acceptability ratewasdefinedas
thepatients completing thequestionnairedividedby thepatientsasked toparticipate;
feasibility rate was the proportion of visiting patients asked to participate. RESULTS:
In total, 177 of 5058 visiting patients, were asked to participate with mean age 47.6
years (standard deviation (SD):17.7) versus 51.6 years (SD:19.0) (p-value0.003) for pa-
tients not asked (n4881). The overall acceptability rate was 93.2% (164/176, one pa-
tient excluded as recorded as both accepted and declined). Mean age for patients
completing the questionnaire was 47.0 years (SD:17.3) versus 51.0 years (SD:17.1) for
patients declining (p-value0.447). There was no difference between genders. The
overall feasibility rate was 3.5%(177/5058): 10.1%(94/929) for Practice-1, 1.1%(16/1529)
for Practice-2, 2.6%(67/2600) for Practice-3. Practices suggested that multiple PDAs
could have been helpful and it was time-consuming to monitor the PDA; however,
they preferred the electronic method over paper questionnaires and were happy to
repeat the experiment. CONCLUSIONS: The high acceptability rate suggests that pa-
tients are prepared to provide electronicQoL data. Thismay also be owing to practices
targeting younger patientswho appearmore familiarwith electronic devices. Though
feasibility ratesdifferedacrosspractices, allwerewilling to takepart again, supporting
electronic QoL data collection.
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WHY ALGORITHM DOESN’T MATTER IN SYNDROMIC SURVEILLANCE: A
COMPARISON OF SYNDROME CLASSIFICATION METHODS
Shin J1, Strylewicz G2, Doctor J1
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OBJECTIVES: Naïve Bayesian networks are used in syndromic surveillance to clas-
sify emergency department chief complaints into disease syndromes and detect
outbreaks in an automated real-time manner. Study objectives were to develop a
modified Bayesian classifier and compare its performance to the naïve Bayesian
classifier. METHODS: Data from the Real-time Outbreak and Disease Surveillance
(RODS) system containing 1000 chief complaints were classified into one of 8 syn-
drome classifications (Gastrointestinal, Constitutional, Respiratory, Rash, Hemor-
rhagic, Botulinic, Neurological, and Other) by a physician. All algorithms in the
studywere comparedwith this standard. The datawere used to develop, train, and
test the naïve and modified Bayesian networks. For each chief complaint, the syn-
drome classification was predicted by using all other chief complaints in the data
set to train the Bayesian network and calculate prior probabilities. Multinomial
logistic regression (MNL) and Classification and Regression Trees (CART) models
were also examined to provide benchmark measures of performance. Kappa sta-
tistics and p-values were calculated. RESULTS: The data set contained only 1 chief
complaint for the Botulinic syndrome, which was consequently excluded from the
study. The remaining 999 chief complaints and 7 syndrome classifications were
used to develop and estimate the models. To simplify the statistical analysis, 68
chief complaints with more than one classification were excluded, resulting in a
total of 931 chief complaints. Kappa statistics for the naive Bayesian network
(©0.85), modified Bayesian network (©0.85), CART (©0.83) and MNL
(©0.86) indicate that all classifiers perform similarly compared to expert classi-
fication (p 0.01 for all kappa statistics). CONCLUSIONS: All methods performed
similarly, suggesting that choice of algorithm in syndrome classification does not
really matter. The CART approach may be preferred over the Bayesian or logistic
approaches as it is rule-based and, therefore, can be easily implemented in virtu-
ally any electronic health record system.
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DOES DIFFERENTIAL DISCOUNTING ENHANCE DECISION MAKING?
O’Mahony J, van Rosmalen J
Erasmus University Medical Center, Rotterdam, The Netherlands
OBJECTIVES: To demonstrate that differential discounting can confuse comparisons
of cost-effectiveness between interventions. In particular, to show that directly com-
paring cost-effectiveness ratios of different interventions from conventional cost-ef-
fectiveness models can result in misleading cost-effectiveness rankings under differ-
ential discounting. METHODS: A simple example of a comparison of the cost-
effectiveness of two hypothetical interventions is used. The first intervention is a
once-off vaccination, which imposes costs in one year alone per patient-cohort. The
second intervention is a therapy for a chronic condition, which imposes costs for
many consecutive years per patient-cohort. Both interventions are assessed on the
conventional basis of a single cohort of patients, resulting in cost-effectiveness esti-
mates for each intervention, which are then compared. An alternative comparison of
cost-effectiveness is then made; it considers the opportunity cost of adopting the
therapy for one cohort of patients in terms of the vaccination that could be provided
for many cohorts over the same period. This alternative comparison yields a second
pair of cost-effectiveness ratios which are compared to those from the conventional
per cohort comparison. RESULTS: Comparing the interventions on the basis of the
actual opportunity cost with the same distribution of spending over time shows the
vaccination to be relatively more cost-effective than under the conventional per co-
hort analysis. Furthermore, the alternative comparison shows the two interventions
to have the same relative cost-effectiveness as if the conventional per cohort compar-
ison had been undertaken with discount rates unadjusted for growth in the cost-
effectiveness threshold (equal discounting). CONCLUSIONS: The debate over differ-
ential discounting has not considered the practical implications for decision making.
Our analysis shows that accounting for threshold growth using differential discount-
ing can make comparisons from conventional forms of cost-effectiveness analysis
misleading as to which interventions are most cost-effective. Accounting for thresh-
old growth using differential discounting is less relevant for decision making than
previously understood.
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COMPARISON OF DISCRETE EVENTS SIMULATION SOFTWARE FOR USE IN
HEALTH ECONOMICS & OUTCOMES RESEARCH
Anaya P
Fundación Mexicana para la Salud AC, Mexico D.F., Mexico
OBJECTIVES: To develop an instrument to assess usefulness of any given simulation
software in theHealth Economics (HE) field and to create a list of available software for
modeling.METHODS: A continued Internet search for available open source or com-
mercial discrete events simulation (DES) software that could be used in the HE field
was performed for four years. Selection of packages included in this study was based
either in having animation or amodule based programming or becausemodels could
beuploaded andaccessed through Internet. Amoredetailed comparison (building the
same model) was made between TreeAge ProSuite, Arena-Basic, Simul8-Basic and
Simul8-Professional with an instrument designed by the author specifically for this
reason including 22 items grouped in three categories: 1) Processing capacity and ease
of use; 2) Adaptability to HE; 3) Transparency and capacity to self-explain. Other pack-
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